Gabriel Schnetzler

8PUBLICATIONS
82CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 13, 2026
Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

|Mar 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.

Maria Vieito, Elisa Fontana, Catherine H Han

|Dec 04, 2025
Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer.

Florian Renner, Jan Eckmann, Cornelia Handl

|Feb 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.

Valentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz

|May 21, 2024
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg-Depleting Antibody.

Sara Belli, Maria Amann, Lucy Hutchinson

|May 18, 2022
Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.

Ester Bonfill-Teixidor, Raffaella Iurlaro, Cornelia Handl

Pageof 2

Frequent Collaborators

4 joint publications

Nino Keshelava

3 joint publications

Elisa Fontana

3 joint publications

Martin Kornacker

3 joint publications

Maria Vieito